Publications by authors named "Lisa Underhill"

Claim this Profile
A
Acid sphingomyelinase deficiency and Gaucher disease: Underdiagnosed and often treatable causes of hepatomegaly, splenomegaly, and low HDL cholesterol in lean individuals.
Pramod K Mistry, David Cassiman, Simon A Jones, Robin Lachmann, Elena Lukina, Lisa H Underhill

Hepatol Commun· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of sphingomyelin on the pathophysiology and treatment response to olipudase alfa in acid sphingomyelinase deficiency.
Monica Kumar, Mario Aguiar, Andreas Jessel, Beth L Thurberg, Lisa Underhill

Genet Med Open· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incentivizing Pregnant Women to Quit Smoking in the Real World-A Community-Based Pilot Intervention.
Bethany Yon, Rhonda Williams, Jennifer Wedin, Lisa Underhill, Allison Kurti

Health Promot Pract· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness of eliglustat in treatment-naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry.
Pramod K Mistry, Manisha Balwani, Joel Charrow, Priya Kishnani, Claus Niederau, Lisa H Underhill

Am J Hematol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.
Pramod K Mistry, Manisha Balwani, Hagit N Baris, Hadhami Ben Turkia, T Andrew Burrow, Lisa H Underhill

Blood Cells Mol Dis· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1.
M Judith Peterschmitt, Selena Freisens, Lisa H Underhill, Meredith C Foster, Grace Lewis

Orphanet J Rare Dis· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.
Pramod K Mistry, Manisha Balwani, Hagit N Baris, Hadhami Ben Turkia, T Andrew Burrow, Lisa H Underhill

Blood Cells Mol Dis· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pooled analysis of adverse events in 393 adults with Gaucher disease type 1 from four clinical trials of oral eliglustat: Evaluation of frequency, timing, and duration.
M Judith Peterschmitt, Gerald F Cox, Jennifer Ibrahim, James MacDougall, Lisa H Underhill

Blood Cells Mol Dis· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial.
Rebecca Pleat, Timothy M Cox, T Andrew Burrow, Pilar Giraldo, Ozlem Goker-Alpan, Lisa H Underhill

Mol Genet Metab Rep· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical response to eliglustat in treatment-naïve patients with Gaucher disease type 1: Post-hoc comparison to imiglucerase-treated patients enrolled in the International Collaborative Gaucher Group Gaucher Registry.
Jennifer Ibrahim, Lisa H Underhill, John S Taylor, Jennifer Angell, M Judith Peterschmitt

Mol Genet Metab Rep· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry.
Kristin D'Aco, Lisa Underhill, Lakshmi Rangachari, Pamela Arn, Gerald F Cox

Eur J Pediatr· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High rate of postoperative mortality in patients with mucopolysaccharidosis I: findings from the MPS I Registry.
Pamela Arn, Chester Whitley, J Edmond Wraith, H Warner Webb, Lisa Underhill

J Pediatr Surg· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnosis of the mucopolysaccharidoses.
Thomas J A Lehman, Nicole Miller, Becky Norquist, Lisa Underhill, Joan Keutzer

Rheumatology (Oxford)· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of surgical procedures in patients with mucopolysaccharidosis type I: findings from the MPS I Registry.
Pamela Arn, J Edmond Wraith, Lisa Underhill

J Pediatr· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The expanded Chronic Care Model: an integration of concepts and strategies from population health promotion and the Chronic Care Model.
Victoria J Barr, Sylvia Robinson, Brenda Marin-Link, Lisa Underhill, Anita Dotts

Hosp Q· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis